Impact of lorlatinib on patient-reported outcomes in patients with advanced ALK-positive or ROS1-positive non-small cell lung cancer-Reference-Cited by-同舟云学术

Impact of lorlatinib on patient-reported outcomes in patients with advanced ALK-positive or ROS1-positive non-small cell lung cancer

Published:2020-06 Issue: Volume:144 Page:10-19
ISSN:0169-5002
Container-title:Lung Cancer
language:en
Short-container-title:Lung Cancer

Author:

Peters Solange,Shaw Alice T.,Besse Benjamin,Felip Enriqueta,Solomon Benjamin J.,Soo Ross A.,Bearz Alessandra,Gadgeel Shirish M.,Lin Chia-Chi^ORCID,Kao Steven,Seto Takashi,Masters Elizabeth T.,Abbattista Antonello,Clancy Jill S.,Thurm Holger,Reisman Arlene,Peltz Gerson,Ross Camidge D.

Funder

Pfizer Inc

Publisher

Elsevier BV

Subject

Cancer Research,Pulmonary and Respiratory Medicine,Oncology

Reference33 articles.

1. Lorlatinib for the treatment of anaplastic lymphoma kinase-positive non-small cell lung cancer;Yang;Expert Rev. Clin. Pharmacol.,2019

2. ROS1 rearrangements define a unique molecular class of lung cancers;Bergethon;J. Clin. Oncol.,2012

3. Clinicopathological characteristics of ROS1- and RET-rearranged NSCLC in caucasian patients: data from a cohort of 713 non-squamous NSCLC lacking KRAS/EGFR/HER2/BRAF/PIK3CA/ALK alterations;Dugay;Oncotarget,2017

4. Efficacy of crizotinib and pemetrexed-based chemotherapy in Chinese NSCLC patients with ROS1 rearrangement;Zhang;Oncotarget,2016

Cited by 16 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. FGFR2 promotes resistance to ALK tyrosine kinase inhibitors and its inhibition acts synergistically with lorlatinib in the treatment of ALK-expressing neuroblastoma;2024-09-10

2. Neurocognitive Adverse Events Related to Lorlatinib in Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis;Cancers;2024-07-22

3. Progress of non-small-cell lung cancer with ROS1 rearrangement;Frontiers in Molecular Biosciences;2023-12-22

4. Safety of lorlatinib in ALK-positive non-small-cell lung cancer and management of central nervous system adverse events;Future Oncology;2023-09

5. The Value of Patient-Reported Outcomes in Single-Arm Cancer Trials;Cancer Investigation;2023-05-02